Proactive Investors - Run By Investors For Investors

Faron Pharma finance boss to transition into new role next month

Yrjö Wichmann is stepping down as CFO to become Faron’s new Vice President, Financing and Investor Relations, and he will be replaced by Toni Hänninen
board room
Hänninen is joining from Fortune 500 group Danaher

Drug developer Faron Pharmaceuticals Ltd’s (LON:FARN) has unveiled plans to reshuffle its boardroom ahead of next week's annual general meeting in Finland.

Chief financial officer Yrjö Wichmann is to step down from his current position to take up the new role of Vice President, Financing and Investor Relations.

READ: Faron raises €1.34mln from existing shareholder

Faron said this will allow him to focus on the company’s “future financing and investor relationships”.

Wichmann will remain a member of the senior management team but will step down from the board next month (June).

Replacing him as CFO will be Toni Hänninen, who will join from Fortune 500 science and technology group Danaher on 1 June.

Hänninen will bring “extensive global experience” which the company said will be “very relevant” as it looks to progress its product portfolio and international commercial development.

‘Changes will strengthen the company’

“These managerial changes will strengthen our operations by allowing Yrjö to focus on the company's future financing,” said chief executive Markku Jalkanen.

“We also believe this will increase Faron's capacity to attract external financing and enable us to better maintain and develop investor relationships and target an expanded future shareholder base.

“I am delighted that Toni has decided to join Faron. His vast experience, from international director and controller positions, will help us to advance our international accounting processes and internal reporting.”

Faron shares were down 0.5% to 103.5p.

View full FARN profile View Profile

Faron Pharmaceuticals Ltd Timeline

Related Articles

February 22 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
scientists in a lab
January 31 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use